{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:24:17Z","timestamp":1789179857869,"version":"build-2803163510"},"reference-count":90,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","rbmojournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive BioMedicine Online"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.rbmo.2016.08.024","type":"journal-article","created":{"date-parts":[[2016,9,17]],"date-time":"2016-09-17T20:20:00Z","timestamp":1474143600000},"page":"770-780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["Inositol as putative integrative treatment for PCOS"],"prefix":"10.1016","volume":"33","author":[{"given":"Alessandro D.","family":"Genazzani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rbmo.2016.08.024_bib0010","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/AOG.0b013e3181bd12cb","article-title":"ACOG Practice bulletin no. 108: polycystic ovary syndrome","volume":"114","author":"ACOG Committee on Practice Bulletins \u2013 Gynecology","year":"2009","journal-title":"Obstet. Gynecol"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0015","doi-asserted-by":"crossref","first-page":"21121","DOI":"10.1074\/jbc.X109.004747","article-title":"Turtles all the way: reflections on myo-inositol","volume":"284","author":"Agranoff","year":"2009","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0020","first-page":"126","article-title":"American association of clinical endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome","volume":"11","author":"American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee","year":"2005","journal-title":"Endocr. Pract"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0025","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/09513590.2012.743020","article-title":"Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. a randomized study","volume":"29","author":"Artini","year":"2013","journal-title":"Gynecol. Endocrinol"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0030","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1073\/pnas.90.13.5924","article-title":"Chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositolcontaining insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects","volume":"90","author":"Asplin","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.rbmo.2016.08.024_bib0035","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1210\/jc.2003-032046","article-title":"The prevalence and features of the polycystic ovary syndrome in an unselected population","volume":"89","author":"Azziz","year":"2004","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1210\/jc.2005-1804","article-title":"Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin?","volume":"91","author":"Baillargeon","year":"2006","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0045","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1210\/jc.2003-030437","article-title":"Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome","volume":"89","author":"Baillargeon","year":"2004","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0050","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2337\/diacare.29.02.06.dc05-1070","article-title":"Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome","volume":"29","author":"Baillargeon","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0055","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/humrep\/den097","article-title":"Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism","volume":"23","author":"Baillargeon","year":"2008","journal-title":"Hum. Reprod"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0060","series-title":"Adipose Tissue and Reproduction","first-page":"42","article-title":"The role of adipose tissue and hyperinsulinemia in the development of hyperandrogenism in women","author":"Barbieri","year":"1990"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0065","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/09513590.2015.1117069","article-title":"Insulin resistance in obesity and polycystic ovary syndrome: systematic review and meta-analysis of observational studies","volume":"32","author":"Behboudi-Gandevani","year":"2016","journal-title":"Gynecol. Endocrinol"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0070","first-page":"1896","article-title":"Inositol: history of an effective therapy for polycystic ovary syndrome","volume":"18","author":"Bizzarri","year":"2014","journal-title":"Eur. Rev. Med. Pharmacol. Sci"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0075","first-page":"478","article-title":"Johann Joseph von Scherer (1814\u201369). The early history of clinical chemistry","volume":"16","author":"Buttner","year":"1978","journal-title":"J. Clin. Chem. Clin. Biochem"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0080","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1016\/j.fertnstert.2011.05.027","article-title":"The D-Chiro-inositol paradox in the ovary","volume":"95","author":"Carlomagno","year":"2011","journal-title":"Fertil. Steril"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0085","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.fertnstert.2013.12.050","article-title":"Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow-up study","volume":"101","author":"Celik","year":"2014","journal-title":"Fertil. Steril"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0090","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4103\/2141-9248.113660","article-title":"Serum leptin level in women with polycystic ovary syndrome: correlation with adiposity, insulin, and circulating testosterone","volume":"3","author":"Chakrabarti","year":"2013","journal-title":"Ann. Med. Health Sci. Res"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0095","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.metabol.2008.05.008","article-title":"Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome","volume":"57","author":"Cheang","year":"2008","journal-title":"Metab. Clin. Exp"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0100","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3109\/09513590.2014.984676","article-title":"Adiponectin and leptin in overweight\/obese and lean women with polycystic ovary syndrome","volume":"31","author":"Chen","year":"2015","journal-title":"Gynecol. Endocrinol"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0105","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/humrep\/17.6.1591","article-title":"Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality","volume":"17","author":"Chiu","year":"2002","journal-title":"Hum. Reprod"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0110","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/humrep\/deg113","article-title":"Effects of myo-inositol on the in-vitro maturation and subsequent development of mouse oocytes","volume":"18","author":"Chiu","year":"2003","journal-title":"Hum. Reprod"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0115","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0026-0495(99)90028-8","article-title":"Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome","volume":"48","author":"Ciampelli","year":"1999","journal-title":"Metabolism"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0120","first-page":"577","article-title":"Cellular mechanisms of insulin resistance in polycystic ovarian syndrome","volume":"75","author":"Ciaraldi","year":"2002","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0125","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2265.1989.tb00446.x","article-title":"Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients","volume":"30","author":"Conway","year":"1989","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0130","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2265.1990.tb03897.x","article-title":"Effects of LH, insulin, insulin-like growth factor I and insulin-like growth factor small binding protein I in the polycystic ovary syndrome","volume":"33","author":"Conway","year":"1990","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0135","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.biochi.2013.05.011","article-title":"Potential role and therapeutic interests of myo-inositol in metabolic diseases","volume":"95","author":"Croze","year":"2013","journal-title":"Biochimie"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0140","first-page":"1","article-title":"The rationale of the myo-inositol and d-chiro-inositol combined treatment for polycycstic ovary syndrome","volume":"20","author":"Dinicola","year":"2014","journal-title":"J. Clin. Pharmacol"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0145","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3121\/cmr.2008.796","article-title":"Neuroendocrine dysfunction in PCOS: a critique of recent reviews","volume":"6","author":"Doi","year":"2008","journal-title":"Clin. Med. Res"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0150","first-page":"774","article-title":"Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis","volume":"18","author":"Dunaif","year":"1997","journal-title":"Endocr. Rev"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0155","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1210\/jc.2013-2040","article-title":"Renaming PCOS: a two state solution","volume":"98","author":"Dunaif","year":"2013","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0160","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1210\/jcem-70-3-699","article-title":"Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in polycystic ovary syndrome","volume":"70","author":"Dunaif","year":"1990","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0165","series-title":"The Polycystic Ovary Syndrome","author":"Dunaif","year":"1992"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0170","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejogrb.2015.09.024","article-title":"Results from the international consensus conference on myo-inositol and d-chiro-inositol in obstetrics and gynecology: the link between metabolic syndrome and PCOS","volume":"95","author":"Facchinetti","year":"2015","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0175","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.fertnstert.2011.09.024","article-title":"Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE\/ASRM-Sponsored 3rd PCOS Consensus Workshop Group","volume":"97","author":"Fauser","year":"2012","journal-title":"Fertil. Steril"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0180","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1590\/S0004-27302009000200020","article-title":"HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome: Brazilian Metabolic Syndrome Study (BRAMS)","volume":"53","author":"Geloneze","year":"2009","journal-title":"Arq. Bras. Endocrinol. Metabol"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0185","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/09513599309152477","article-title":"The concomitant release of androstenedione with cortisol and luteinizing hormone pulsatile releases distinguishes adrenal from ovarian hyperandrogenism","volume":"7","author":"Genazzani","year":"1993","journal-title":"Gynecol. Endocrinol"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0190","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.fertnstert.2003.05.020","article-title":"Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome","volume":"81","author":"Genazzani","year":"2004","journal-title":"Fertil. Steril"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0195","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1080\/09513590701214398","article-title":"Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia","volume":"23","author":"Genazzani","year":"2007","journal-title":"Gynecol. Endocrinol"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0200","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/09513590801893232","article-title":"Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome","volume":"24","author":"Genazzani","year":"2008","journal-title":"Gynecol. Endocrinol"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0205","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2217\/whe.10.43","article-title":"Use of metformin in the treatment of polycystic ovary syndrome","volume":"6","author":"Genazzani","year":"2010","journal-title":"Womens Health (Lond)"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0210","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3109\/09513590.2012.685205","article-title":"Differential insulin response to myo-inositol administration in obese PCOS patients","volume":"28","author":"Genazzani","year":"2012","journal-title":"Gynecol. Endocrinol"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4172\/2161-1017.1000140","article-title":"Effects of a combination of alpha lipoic acid and myo-inositol on insulin dynamics in overweight\/obese patients with PCOS","volume":"3","author":"Genazzani","year":"2014","journal-title":"Endocrinol. Metab. Synd"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0220","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3109\/09513590.2014.897321","article-title":"Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients","volume":"30","author":"Genazzani","year":"2014","journal-title":"Gynecol. Endocrinol"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0225","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.4158\/EP15748.DSC","article-title":"American Asociation of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome \u2013 part 1","volume":"21","author":"Goodman","year":"2015","journal-title":"Endocr. Pract"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0230","first-page":"209","article-title":"Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth","volume":"68","author":"Harwood","year":"2007","journal-title":"Horm. Res"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0235","first-page":"529","article-title":"Polycystic ovary syndrome, obesity and reproductive implications","volume":"5","author":"Hirschberg","year":"2009","journal-title":"Womens Health"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0240","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/humrep\/der065","article-title":"Diabetes and impaired glucose tolerance in patients with polycystic ovary syndrome\u2013a long term follow-up","volume":"26","author":"Hudecova","year":"2011","journal-title":"Hum. Reprod"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0245","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4158\/EP.8.6.417","article-title":"Effects of d-chiroinositol in lean women with the polycystic ovary syndrome","volume":"8","author":"Iuorno","year":"2002","journal-title":"Endocr. Pract"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0250","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/humupd\/5.2.166","article-title":"Leptin, polycystic ovaries and polycystic ovary syndrome","volume":"5","author":"Jacobs","year":"1999","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0255","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/09513590.2014.964640","article-title":"Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance","volume":"31","author":"Kamenov","year":"2015","journal-title":"Gynecol. Endocrinol"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0260","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJM199008093230603","article-title":"Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus","volume":"323","author":"Kennington","year":"1990","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0265","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1210\/jcem-70-2-473","article-title":"Androgen-estrogen metabolism in women with upper body versus lower body obesity","volume":"70","author":"Kirschner","year":"1990","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0270","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s00134-007-0788-7","article-title":"The first demonstration of lactic acid in human blood in shock by Johann Joseph Scherer (1814\u20131869) in January 1843","volume":"33","author":"Kompanje","year":"2007","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0275","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/09513590.2014.964201","article-title":"The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study","volume":"31","author":"La Marca","year":"2015","journal-title":"Gynecol. Endocrinol"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0280","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/15604280212528","article-title":"D-Chiro-Inositol: its functional role in insulin action and its deficit in insulin resistance","volume":"3","author":"Larner","year":"2002","journal-title":"Int. J. Exp. Diabetes Res"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0285","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2337\/diacare.19.1.76","article-title":"Urinary myo-inositol-tochiro-inositol ratios and insulin resistance","volume":"19","author":"Larner","year":"1996","journal-title":"Diabetes Care"},{"issue":"Pt 2","key":"10.1016\/j.rbmo.2016.08.024_bib0290","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1101\/SQB.1988.053.01.111","article-title":"Insulin mediators: structure and formation","volume":"53","author":"Larner","year":"1988","journal-title":"Cold Spring Harb. Symp. Quant. Biol"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0295","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2119\/molmed.2010.00107","article-title":"D-chiro-inositol glycans in insulin signaling and insulin resistance","volume":"16","author":"Larner","year":"2010","journal-title":"Mol. Med"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0300","first-page":"2694","article-title":"Fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome","volume":"83","author":"Legro","year":"1998","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0305","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1530\/jrf.0.0690215","article-title":"Activity of myo-inositol-1-phosphate synthase in the epididymal spermatozoa of rams","volume":"69","author":"Loewus","year":"1983","journal-title":"J. Reprod. Fertil"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0310","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/bmj.327.7421.951","article-title":"Metformin in polycystic ovary syndrome: systematic review and meta-analysis","volume":"327","author":"Lord","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0315","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3109\/09513590.2013.774362","article-title":"Accurate screening for insulin resistance in PCOS women using fasting insulin concentrations","volume":"29","author":"Lunger","year":"2013","journal-title":"Gynecol. Endocrinol"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0320","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1590\/S0004-27302008000900010","article-title":"Cut-off point for Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) index established from Receiver Operating Characteristic (ROC) curve in the detection of metabolic syndrome in overweight prepubertal children","volume":"52","author":"Madeira","year":"2008","journal-title":"Arq. Bras. Endocrinol. Metabol"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0325","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00404-006-0171-x","article-title":"Polycystic ovary syndrome: etiology and pathogenesis","volume":"274","author":"Matalliotakis","year":"2006","journal-title":"Arch. Gynecol. Obstet"},{"issue":"7","key":"10.1016\/j.rbmo.2016.08.024_bib0330","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007506.pub3","article-title":"Lifestyle changes in women with polycystic ovary syndrome","author":"Moran","year":"2011","journal-title":"Cochrane Database Syst. Rev"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0335","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1210\/jcem.86.12.8088","article-title":"The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome","volume":"86","author":"Nelson","year":"2001","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0345","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1056\/NEJMct0707092","article-title":"Metformin for the treatment of the polycystic ovary syndrome","volume":"358","author":"Nestler","year":"2008","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0350","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.metabol.2008.05.008","article-title":"Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome","volume":"57","author":"Nestler","year":"2008","journal-title":"Metab. Clin. Exp"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0355","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJM199904293401703","article-title":"Ovulatory and metabolic effects of D-chiroinositol in the polycystic ovary syndrome","volume":"340","author":"Nestler","year":"1999","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0360","first-page":"575","article-title":"The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone","volume":"16","author":"Nordio","year":"2012","journal-title":"Eur. Rev. Med. Pharmacol. Sci"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0365","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1210\/endo.132.2.8425483","article-title":"Chiroinositol deficiency and insulin resistance. I. Urinary excretion rate of chiroinositol is directly associated with insulin resistance in spontaneously diabetic rhesus monkeys","volume":"132","author":"Ortmeyer","year":"1993","journal-title":"Endocrinology"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0370","doi-asserted-by":"crossref","first-page":"7759","DOI":"10.1073\/pnas.90.16.7759","article-title":"Insulin stimulates the biosynthesis of chiro-inositolcontaining phospholipids in a rat fibroblast line expressing the human insulin receptor","volume":"90","author":"Pak","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.rbmo.2016.08.024_bib0375","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1016-8478(23)13428-5","article-title":"In vivo chiro-inositol metabolism in the rat: a defect in chiro-inositol synthesis from myo-inositol and an increased incorporation of chiro-[3H]inositol into phospholipid in the Goto-Kakizaki (G.K) rat","volume":"8","author":"Pak","year":"1998","journal-title":"Mol. Cells"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0380","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1530\/eje.1.02156","article-title":"Insulin-sensitizing agents in polycystic ovary syndrome","volume":"154","author":"Pasquali","year":"2006","journal-title":"Eur. J. Endocrinol"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0385","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0002-9378(86)90410-2","article-title":"Effect of weight loss and antiandrogenic therapy on sex hormone blood levels and insuline resistance in obese patients with polycystic ovaries","volume":"154","author":"Pasquali","year":"1986","journal-title":"Am. J. Obstet. Gynecol"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0390","first-page":"1","article-title":"Glucose tolerance, insulin secretion and insulin sensitivity in polycystic ovary syndrome","volume":"3","author":"Pasquali","year":"2002","journal-title":"JOP J. Pancreas (Online)"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0395","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1210\/jcem-64-1-162","article-title":"Relationship of androgenic activity to splanchnic insulin metabolism and peripheral glucose utilization in premenopausal women","volume":"64","author":"Peiris","year":"1987","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0400","first-page":"791","article-title":"Effect of testosterone on abdominal adipose tissue in men","volume":"15","author":"Rebuffe-Scrive","year":"1991","journal-title":"Int. J. Obes"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0405","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/humrep\/deh609","article-title":"Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries","volume":"20","author":"Rice","year":"2005","journal-title":"Hum. Reprod"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0410","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1757-2215-5-14","article-title":"Does ovary need D-chiroinositol?","volume":"5","author":"Rosalbino","year":"2012","journal-title":"J. Ovarian Res"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0420","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tem.2003.08.002","article-title":"Polycystic ovary syndrome: syndrome XX?","volume":"14","author":"Sam","year":"2003","journal-title":"Trends Endocrinol. Metab"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0425","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1055\/s-2002-34785","article-title":"Adiponectin \u2013 its role in metabolism and beyond","volume":"34","author":"Stefan","year":"2002","journal-title":"Horm. Metab. Res"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0430","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S0006-291X(02)00313-3","article-title":"Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls","volume":"293","author":"Sun","year":"2002","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0435","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycycstic ovary syndrome","volume":"81","year":"2004","journal-title":"Fertil. Steril"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0440","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1210\/en.2010-1353","article-title":"The adapter protein APPL1 links FSH receptor to inositol 1,4,5-trisphosphate production and is implicated in intracellular Ca2_ mobilization","volume":"152","author":"Thomas","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0445","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2796.2004.01426.x","article-title":"Adiponectin \u2013 journey from an adipocyte secretory protein to biomarker of the metabolic syndrome","volume":"257","author":"Trujillo","year":"2005","journal-title":"J. Intern. Med"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0450","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/09513590.2011.650660","article-title":"Effects of myo-inositol in women with PCOS: a systematic review iof randomized controlled trials","volume":"28","author":"Unfer","year":"2012","journal-title":"Gynecol. Endocrinol"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0455","first-page":"2","article-title":"Polycystic ovary syndrome: features, diagnostic criteria and treatments","volume":"3","author":"Unfer","year":"2014","journal-title":"Endocrinol. Metab. Synd"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0460","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000194971","article-title":"Obesity and polycystic ovary syndrome","volume":"2","author":"Vrbikova","year":"2009","journal-title":"Obes. Facts"},{"key":"10.1016\/j.rbmo.2016.08.024_bib0465","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1210\/jc.2009-2724","article-title":"Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary Ovary Syndrome (AE-PCOS) Society","volume":"95","author":"Wild","year":"2010","journal-title":"J. Clin. Endocrinol. Metab"}],"container-title":["Reproductive BioMedicine Online"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472648316305089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472648316305089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T12:17:51Z","timestamp":1718799471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472648316305089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":90,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S1472648316305089"],"URL":"https:\/\/doi.org\/10.1016\/j.rbmo.2016.08.024","relation":{},"ISSN":["1472-6483"],"issn-type":[{"value":"1472-6483","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inositol as putative integrative treatment for PCOS","name":"articletitle","label":"Article Title"},{"value":"Reproductive BioMedicine Online","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rbmo.2016.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}